Cadila Healthcare Gets Final Nod From USFDA To Market Tizanidine Capsules


Pharmaceutical giant Cadila Healthcare Limited has bagged the final approval from the USFDA to market Tizanidine Hydrochloride capsules, USP in strengths of 2mg, 4mg, and 6mg. The drug is widely used as a muscle relaxant, will be produced at the SEZ facility located in Ahmedabad.

The approximate sales for Tizanidine Hydrochloride capsules are more than $ 58.6 million as per record of IMS till Jan 2017. The group has now more than 109 approvals in their kitty and the company has so far filed more than 300 ANDAs since the beginning of the filing process in FY2003-04.

For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: